|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12 Suppl
|
|
pubmed:dateCreated |
1998-1-2
|
|
pubmed:abstractText |
The beneficial effects of radioimmunotherapy (RIT) may result from activation of molecular pathways that lead to programmed cell death (apoptosis). The influences of sequence and timing of 90Y-DOTA-peptide-ChL6 antibody (90Y-ChL6) and anti-epidermal growth factor receptor antibody (ch225) or paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) on efficacy and toxicity were examined.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2583-90
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9406713-Animals,
pubmed-meshheading:9406713-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9406713-Bone Marrow,
pubmed-meshheading:9406713-Combined Modality Therapy,
pubmed-meshheading:9406713-Female,
pubmed-meshheading:9406713-Humans,
pubmed-meshheading:9406713-Mammary Neoplasms, Experimental,
pubmed-meshheading:9406713-Mice,
pubmed-meshheading:9406713-Mice, Inbred BALB C,
pubmed-meshheading:9406713-Mice, Nude,
pubmed-meshheading:9406713-Paclitaxel,
pubmed-meshheading:9406713-Radioimmunotherapy,
pubmed-meshheading:9406713-Tumor Cells, Cultured,
pubmed-meshheading:9406713-Weight Loss,
pubmed-meshheading:9406713-Yttrium Radioisotopes
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma.
|
|
pubmed:affiliation |
Department of Internal Medicine, University of California Davis Medical Center, Sacramento, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|
